https://orcid.org/0000-0002-3458-1697
Figures
Abstract
Background
With the advancement of next-generation sequencing, clinicians are now able to detect ultra-rare mutations that are barely encountered by the majority of physicians. Ultra-rare and rare diseases cumulatively acquire a prevalence equivalent to type 2 diabetes with 80% being genetic in origin and more prevalent among high consanguinity communities including Saudi Arabia. The challenge of these diseases is the ability to predict their prevalence and define clear phenotypic features.
Methods
This is a non-interventional retrospective multicenter study. We included pediatric patients with a pathogenic variant designated as ultra-rare according to the National Institute for Clinical Excellence’s criteria. Demographic, clinical, laboratory, and radiological data of all patients were collected and analyzed using multinomial regression models.
Results
We included 30 patients. Their mean age of diagnosis was 16.77 months (range 3–96 months) and their current age was 8.83 years (range = 2–15 years). Eleven patients were females and 19 were males. The majority were of Arab ethnicity (96.77%). Twelve patients were West-Saudis and 8 patients were South-Saudis. SCN1A mutation was reported among 19 patients. Other mutations included SZT2, ROGDI, PRF1, ATP1A3, and SHANK3. The heterozygous mutation was reported among 67.86%. Twenty-nine patients experienced seizures with GTC being the most frequently reported semiology. The mean response to ASMs was 45.50% (range 0–100%).
Citation: Muthaffar OY, Alazhary NW, Alyazidi AS, Alsubaie MA, Bahowarth SY, Odeh NB, et al. (2024) Clinical description and evaluation of 30 pediatric patients with ultra-rare diseases: A multicenter study with real-world data from Saudi Arabia. PLoS ONE 19(7): e0307454. https://doi.org/10.1371/journal.pone.0307454
Editor: Laith Al-Eitan, Jordan University of Science and Technology, JORDAN
Received: February 10, 2024; Accepted: July 4, 2024; Published: July 18, 2024
Copyright: © 2024 Muthaffar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data cannot be shared publicly because of patients' privacy. Data are available from the Unit of Biomedical Research at King Abdulaziz University (contact via med.rcommittee@kau.edu.sa) for researchers who meet the criteria for access to confidential data.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
For millions of children, everyday life is a medical mystery. They battle undiagnosed illnesses, leaving doctors baffled and families desperate. These silent struggles often stem from ultra-rare diseases (URD), debilitating conditions affecting fewer than 1 in 50,000 individuals [1–4]. In recent years, medicine and research underwent huge advancement with the emergence of new diagnostic modalities including next-generation sequencing (NGS) which became the core technology for gene discovery giving practicing clinicians the ability to detect novel mutations [5–8]. NGS can be utilized to scan and sequence thousands of genes including all 22,000 coding genes (a whole exome) or small numbers of individual genes [8] leading to a significant increase in the mutation detection rate [9]. In this sense, many of the newly detected novel variants are rare and barely encountered by the majority of physicians; in the United States, for example, it is estimated that 30 million people suffer from some type of rare disease, a prevalence equivalent to type 2 diabetes [10]. This can lead to underdiagnosing or even misdiagnosing patients with such conditions. Many of those patients subsequently receive symptomatic therapy despite the ability to provide optimal care and avoid patients exposed to unnecessary treatments, unfavorable side effects, and diagnostic odyssey if diagnosed adequately [11]. Furthermore, 80% of rare diseases are genetic in origin [12, 13] and can be inherited which puts additional focus on halting and preventing disease passage to the next generations [14]. The topic is of greater importance in countries such as Saudi Arabia in which the prevalence of consanguineous marriages is estimated to be as high as 50% of all marriages [15]. The increased risk of genetic disorders, foremost rare and URDs, is one of the main concerns associated with consanguineous marriages [16]. Reproduction between closely related individuals increases the likelihood that both parents have the same genetic mutation and subsequently their children are more likely to have recessive genetic disorders as a result of this circumstance [16]. Nonetheless, the diagnostic delay for rare diseases is of broad interval with some literature suggesting a mean of four to five years to reach the correct diagnosis [17–19]. Recently, the term "ultra-rare diseases" was used to describe rare diseases with an incidence of less than one in fifty thousand [1–3] that are likely to exist among patients with undiagnosed rare diseases [20]. The challenges with URD are due to their possibility of representing a very large group of disorders of unknown future prevalence and our ability to define the phenotypic features [21, 22]. In this study, we shed light on seven such URD through the lens of thirty cases encountered at our tertiary care centers. By delving into their clinical features and the hurdles faced in diagnosis and treatment, we aim to contribute to the crucial task of unraveling the mysteries of these hidden illnesses and paving the way for better care for the millions living in uncertainty.
Materials and methods
Ethics statement
The study received ethical approval for its protocol and procedures from the Unit of Biomedical Research Ethics at the Faculty of Medicine in King Abdulaziz University on July 12, 2023, with reference number (265–23). Patients privacy and confidentiality was ensured throughout the conducting of this research and all revealing data were masked accordingly. Written informed consent was obtained to publish the details of the reported cases from the patient’s legal parents after describing the nature of the published information, its uses, and the research objectives. This study was performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments.
Study design and setting
This is a non-interventional retrospective multicenter study based on an anonymized chart review using the electronic hospital record to identify the targeted population. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for retrospective studies [23]. The centers of the study included a publicly operated academic tertiary care center, funded and owned, that serves the entire community with a bed capacity of 750. The second center is a privately-owned tertiary care center, with a bed capacity of 300. The third center is a major referral center at the national level mainly providing care to complex cases for patients with special needs with advanced medical services. All three centers are located in a city with high population diversity located on the western coasts of Saudi Arabia. This ensured the heterogeneity of the included sample. Patients aged 14 years and younger currently and following up in the pediatric neurology clinics with a confirmed diagnosis of an URD were included. Diseases identified as ultra-rare according to the following criteria: A) Disease prevalence is 1:50,000 or lower, B) Diseases registered at the National Organization for Rare Disorders (NORD) database for rare diseases. This criteria was adopted in accordance with the National Institute for Clinical Excellence (NICE) definition of URD [24]. The variant classification criteria were based on the American College of Medical Genetics and Genomics (ACMG) recommendations for standards for interpretation and reporting of sequence variations (Class 1: Pathogenic, Class 2: Likely pathogenic, Class 3: Variant of uncertain significance [VUS], Class 4: Likely benign, Class 5: Benign) [25].
Study procedure
After obtaining ethical clearance, we retrospectively screened the electronic hospital records and included patients visiting the pediatric neurology clinics during the period of January 1 to August 10, 2023. On August 10, 2023, we extracted data directly from the records to minimize errors, focusing on 356 patient visits within that timeframe. This led to the identification of 30 potential cases, whose medical history and demographic information were further reviewed. With informed consent from their families, we then collected detailed data across various categories, including:
- Genetics: genetic variants, homozygosity, alleles, and the specific genetic test used for diagnosis (e.g., whole exome sequencing).
- Demographics: gender, ethnicity, origin, current age, age of diagnosis, type of admission (emergency or outpatient), and baseline laboratory workup
- Birth parameters: term, weight, height, head circumference, pregnancy outcome, neonatal period.
- Seizure characteristics: etiology, semiology, medications used, and response to treatment.
- Clinical information: relevant medical history and observations.
- Developmental history: cognitive, sensorimotor, speech, language, and socioemotional development.
- Imaging and electrophysiological findings: X-rays, MRIs, and electroencephalograms (EEGs).
Sample collection
Patients with URD were identified using next-generation sequencing (NGS). To implement such procedures, we followed appropriate ethical and logistical measures adopted in our local institution and obtained the genetic sample of the patients at King Abdulaziz University Hospital. DNA capture probes using NGS-based copy number variation (CNV) analysis with Illumina array were performed. The coding regions of the gene and known pathogenic/likely pathogenic variants within the gene (coding and non-coding) were targeted for analysis. Data analysis, variant calling and annotation were performed using validated software [26]. Further prioritization was performed focusing on rare variants that were loss of function (frameshift, nonsense, and splice site mutations), homozygous missense, and/or affecting known disease genes from the Online Mendelian Inheritance in Man database (OMIM). Several prediction tools were used to predict the pathogenicity of the identified variant. The children’s variant inheritance mode was compared to the parents’ exome sequencing results.
Data analysis
Data were collected in a Microsoft Excel (Microsoft® Corp., Redmond, WA, USA) version 20 sheet. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 27 (IBM Corp., Armonk, NY, USA) and SmartPLS 3. Numerical variables were analyzed and described as means and standard deviations (σ). Measures of central tendency were calculated to describe quantitative variables. One-way analysis of variance (ANOVA) and multinomial regression were used to analyze statistical differences between groups. Variable independence was measured by the Likelihood Ratio (LR) Chi statistic and Fisher’s exact test. Nominal parameters were compared using the chi-squared test. The Bonferroni correction was used in post hoc testing of the data. The level of significance, (P-value), was determined at <0.05 and 95% confidence intervals.
Results
Patient population
Our study examined a cohort of 30 pediatric patients diagnosed with URD, adhering to established classification criteria. With an average age of 8.83 years (SD 3.90), all participants fell within the pediatric range (< 14 years old). Notably, the average age of diagnosis was significantly later at 16.77 months (SD 19.39). Nineteen participants were male, and the majority (96.77%) identified as Arab ethnicity, with the remaining comprising Pashtun and Berber individuals. Geographical distribution revealed most patients originated from the western and southern regions of Saudi Arabia. Consanguinity within parents was confirmed in a striking 80% of cases, with a reported heterozygous mutation in 67.86% of these familial instances. Among the identified ultra-rare mutations, the SCN1A gene (sodium voltage-gated channel alpha subunit 1) stood out, affecting 19 patients. Additional mutations were found in SZT2 (Seizure Threshold 2), ROGDI (Rogdi Atypical Leucine Zipper), PRF1 (Perforin 1), ATP1A3 (ATPase Na+/K+ Transporting Subunit Alpha 3), and SHANK3 (SH3 and multiple ankyrin repeat domains 3) genes across the remaining participants (Fig 1).
Genetic data
Of those mutations, two siblings with a homozygous mutation in SZT2 c.6113A>Cp. (Tyr2038Ser) (NM_015284.3) suspecting a diagnosis of autosomal recessive developmental and epileptic encephalopathy (DEE) type 18. Their parents were found to be heterozygous for the same mutation in the SZT2 gene. On the other hand, one patient was found to carry two copies of a specific ROGDI gene variant: one inherited from each parent as follows: inherited c.117+1G>A chr16:4802381C>T (NM_024589.3) from this father and c.117+1G>A chr16:4802381C>T (NM_024589.3) from his mother. This variant, classified as likely pathogenic, has been linked to Kohlschutter-Tonz syndrome (KTS). Regarding the patients carrying a variant in the PRF1 gene, whole exome sequence (WES) testing revealed a homozygous mutation in the PRF1 gene and was subsequently validated by Sanger sequencing. A sequence variant of c.1081A>T (p.Arg361Trp) (NM_001083116.3) was identified in the patient. Her elder sibling has also revealed a (NM_001083116.3):c.1081A>T (p.Arg361Trp) homozygous variant within the same gene. Both patients were associated with hemophagocytic lymphohistiocytosis (HLH) disease. No parental testing was carried out on the patients. As for the patient carrying a variant in the ATP1A3 gene, her diagnosis was established using whole genome sequencing (WGS) after performing an inconclusive WES testing. Her mutation was a heterozygous, potential de novo, VUS of (ATP1A3, c.29C>T, p-[Ser10Leu]). Also, two homozygous variants were identified in this patient as follows, (NHLRC2, c.335G>T, p. (Gly112Val) and MAPRE2 c.55C>T, p.[GIn19*]) which do not match with clinical phenotypes. The second patient carrying a variant in the same gene with a potential de novo mutation and heterozygous genotype of ATP1A3, c.2366C>A, p.(Pro789Gln) which is likely a pathogenic variant. Similarly to the first case, ATP1A3 mutation was detected by WGS rather than WES. Concerning the patient carrying the SHANK3 variant, his WES identified a heterozygous likely pathogenic variant in the SHANK3 gene, (Chr22(GRCh37):g.51153476G>A, NM_001080420.1:c.2313+1G>A), the c.2313+1G>A variant is predicted to disrupt the highly conserved donor splice site of exon 20. A genetic diagnosis of autosomal dominant Phelan-McDermid syndrome was confirmed in this patient. Table 1 shows detailed patients’ demographics and clinical characteristics.
Clinical and electrographic spectrum
Table 2 comprehensively outlines the clinical and behavioral features, developmental delays, comorbidities, as well as magnetic resonance imaging (MRI) and electroencephalogram (EEG) abnormalities in patients affected by URD. In the examined patient cohort, 20% displayed abnormal gait, and 13.3% presented with infantile hypotonia. Attention-deficit/hyperactivity disorder (ADHD) was noted in 23.3% of the patients, while 10% were diagnosed with autism spectrum disorder. Global developmental delay was evident in 26.7% of cases, with speech impairment being the most prevalent manifestation (46.7%). Abnormal EEG findings were documented in 53.3% of patients, and 16.7% exhibited abnormalities in MRI scans.
Seizures and antiseizure medications
Seizures were observed in 28 cases with generalized tonic-clonic being the most reported (76.7%), followed by febrile seizures (40%) and myoclonic seizures (23.3%). Fig 2 illustrates the distribution of observed seizure types. Table 3 shows the antiseizure medications (ASMs) used for patients with URD, outlining both current usage and previous unsuccessful trials. Valproic acid (60%), clobazam (53.3%), and levetiracetam (40%) were the most currently used ASMs. However, levetiracetam had the highest failure rate (33.3%). Most of the patients (73.3%) were currently on three or more ASMs, with an overall mean response of 45.50%. The most notable response, reaching 100%, was observed in a patient with the ROGDI variant. Following closely were two patients with the SZT2 variant, exhibiting a response rate of 90%. Both ATP1A3 and SHANK3 mutations showed a response rate of 80%. Patients with GAMT, SCN1A, and PCDH19 mutations demonstrated response rates of 66.67%, 36.84%, and 25%, respectively. Conversely, patients with the PRF1 variant displayed no response to ASMs. The detailed breakdown of the response to ASM for each genetic mutation is presented in Table 4.
Discussion
Pediatric URD, defined by their exceptional rarity and devastating impact, presents a crucial but daunting research frontier. Their low prevalence fuels a cascade of challenges: limited understanding, scarce data, and frequent diagnostic delays or misdiagnoses [27]. This "diagnostic odyssey" inflicts emotional and financial burdens on families and emphasizes the urgent need for heightened awareness among healthcare providers, advanced diagnostic tools for faster and more accurate diagnoses, and collaborative efforts to expedite interventions and improve patient outcomes [28]. Beyond clinical care, research on these enigmatic conditions faces its own formidable obstacles. Limited patient pools, fragmented data, and the absence of standardized protocols obstruct the design and execution of clinical trials and studies. To overcome these hurdles, innovative approaches are key, including international collaborations to pool resources and expertise, establishment of patient registries to facilitate data collection and research efforts, and leveraging cutting-edge technologies like genomics to unlock disease mechanisms and identify potential therapeutic targets [29].
Our study included thirty patients with URD according to the previously established classification (Table 5). The average age at the time of data collection was 8.83 years and the mean age of diagnosis was found to be 16.77 months. All our studied patients were within the pediatric age group (<14 years old). Most of them were of Arab ethnicity (96.77%) others included Pashtun and Berber. Consanguinity among parents existed in most cases (80%). Furthermore, our patient population showed positive results for the SCN1A (sodium voltage-gated channel alpha subunit 1) mutation which was detected in 19 patients. Additionally, we identified mutations in SZT2 (Seizure Threshold 2), ROGDI (Rogdi Atypical Leucine Zipper), PRF1 (Perforin 1), ATP1A3 (ATPase Na+/K+ Transporting Subunit Alpha 3), and SHANK3 (SH3 and multiple ankyrin repeat domains 3) genes among the remaining patients. These genes have been rarely reported in previously published studies in Saudi Arabia.
Molecularly, the SCN1A mutation, which was detected in 19 patients, encodes the alpha subunit of the sodium voltage-gated channel, which plays a crucial role in the generation and propagation of action potentials in neurons [30, 31]. Mutations in SCN1A have been associated with various seizure disorders and epilepsy syndromes [32]. The identified SCN1A mutations may have significant implications for protein function. These mutations can disrupt the normal functioning of the sodium channel, leading to altered excitability and impaired neuronal signaling [31]. This can result in increased susceptibility to seizures and contribute to the pathogenesis of epilepsy in affected individuals [31, 32]. Furthermore, we identified mutations in SZT2, which is involved in regulating seizure threshold and synaptic transmission [33]. The exact role of SZT2 in epilepsy is still under investigation, but mutations in this gene have been implicated in various forms of epilepsy [34]. The interpretation of SZT2 mutations requires careful examination of their potential impact on protein function. Disruptive mutations in SZT2 may affect its ability to modulate synaptic activity and neuronal excitability, leading to an increased risk of seizures [35]. Moreover, as for the ROGDI mutation, it may affect protein stability, interactions with other cellular components, or signaling pathways involved in neuronal development and function and eventually causing KTS [36]. Also, the interpretation of PRF1 mutation involves assessing their impact on perforin function and immune response regulation [37, 38]. The mutation can impair perforin-mediated cytotoxicity, leading to defective immune surveillance and hyperinflammatory responses [39]. Additionally, an ATP1A3 variant have been associated with a spectrum of neurological disorders which includes alternating hemiplegia of childhood (AHC) and rapid-onset dystonia-parkinsonism (RDP) [40]. Interpreting ATP1A3 mutations involves assessing their impact on ion transport and neuronal excitability [41]. Mutations can disrupt the function of the Na+/K+-ATPase pump, leading to altered ion homeostasis and impaired neuronal signaling [41]. These disruptions can manifest as neurological symptoms, such as hemiplegia, dystonia, and parkinsonism [42]. Moving forward to SHANK3 which is a postsynaptic scaffolding protein involved in the organization and function of synapses [43], a mutation in SHANK3 have been primarily associated with Phelan-McDermid syndrome, similarly in our patient, the syndrome is characterized with a neurodevelopmental disorder characterized by intellectual disability, autism spectrum disorder, and seizures [44]. The sequel is due to a structure and function of the SHANK3 protein, leading to synaptic dysfunction and altered neuronal circuits [43]. Disease severity, age of onset, disease progression, and comorbidities may also be important factors impacting the effectiveness of ASMs.
Clinically, seizures can be a common manifestation of various URD affecting children [45]. In our study, Seizures were observed in 28 cases with generalized tonic-clonic being the most reported (76.7%), followed by febrile seizures (40%) and myoclonic seizures (23.3%). These seizures often present unique challenges due to the rarity and complexity of the underlying conditions. Many URD, such as certain metabolic disorders, neuronal migration disorders, or specific genetic syndromes, may have seizures as a prominent feature [45, 46]. The occurrence of seizures in these conditions can vary widely in presentation and severity, making diagnosis and management intricate tasks [45]. Moreover, seizures presenting with URD might be refractory to standard antiepileptic medications, necessitating tailored treatment approaches that address the specific genetic or metabolic abnormalities driving the seizures [45]. Most of our patients (73.3%) were on three or more ASMs, with an overall mean response of 45.50%. Comprehensive care involving multidisciplinary teams comprising neurologists, geneticists, and other specialists is crucial for accurate diagnosis, ongoing monitoring, and implementing personalized treatment strategies to manage seizures effectively in children with URD [47]. Regarding seizure response, patients reported variation in their response which can be attributed to multiple causes. This can include the gene-drug interactions, polymorphisms, or specific genetic variants that could influence drug metabolism, target engagement, or drug response pathways [48]. Also, factors such as drug absorption, distribution, metabolism, and elimination, as well as target engagement and downstream signaling pathways, can influence the efficacy of ASMs [49]. Recently, evidence of genetic markers, neuroimaging findings, EEG findings, or other molecular indicators, can serve as predictors of treatment response [50, 51].
Moreover, continued research endeavors aim to uncover the underlying mechanisms of seizures in these conditions, paving the way for more targeted and effective therapies that improve the quality of life for affected children. Nonetheless, numerous research studies have tackled the intricate landscape of URD within pediatric populations, striving to illuminate the challenges and potential pathways for better understanding and managing these conditions. A study published in the Orphanet Journal of Rare Diseases (2023) delved into the epidemiology and clinical characteristics of URD in children [52]. Through conducting interviews with patients and their families, the study emphasized the substantial diagnostic delays and the profound psychological impact on patients and families [52]. Also, another article published in 2020 discussed the emerging role of genomic technologies, such as whole-exome sequencing and gene panel testing, in elucidating the genetic basis of URD in pediatric cohorts, emphasizing the potential for personalized and targeted therapies. These studies collectively underscore the complexity of these conditions, emphasizing the imperative for collaborative efforts, innovative diagnostic tools, and targeted interventions to address the unmet needs of children affected by URD [53]. Fueled by its high consanguinity rate and potential link to URD, Saudi Arabia is emerging as a critical hub for research in this challenging field. By illuminating the unique epidemiological, diagnostic, and clinical aspects within the Saudi context, researchers can shed light on these enigmatic conditions and tailor solutions for the region’s specific needs. Several landmark studies published in medical journals have paved the way for this growing area of interest. One recent example, published in 2023, explored the diverse spectrum of ultra-rare genetic disorders affecting children in the Saudi healthcare system. This study highlighted the challenges in managing these conditions and emphasized the need for enhanced diagnostic capabilities and multidisciplinary care approaches [54]. Another study, published in 2017, focused on specific URD, revealing crucial insights into the unique genetic landscape and disease patterns prevalent in Saudi children [55]. Our study adds immense value to the current literature as URD is not studied sufficiently. This calls for more efforts towards early genetic testing and early diagnosis to help establish appropriate care and increase the patient’s life expectancy.
Limitations
The study was limited by the absence of comparative literature to compare the findings and the inability to perform functional analysis due to resource constraints. This limitation arises when studying URD that have limited existing literature especially for patients with similar ethnicity and background.
Conclusion
The research indicates that classifying URD separately from rare diseases may be warranted due to potential differences in demographics and clinical presentation. Establishing additional objective and descriptive criteria for case identification is crucial. Additionally, our findings emphasize the importance of early genetic testing and diagnosis for individuals with URD. Timely identification of these mutations enables physicians to offer accurate information, appropriate counseling, and tailored care plans to affected patients and their families. Early diagnosis also facilitates the implementation of targeted interventions and personalized therapies, which can significantly improve patient outcomes and quality of life. Furthermore, our study underscores the need for enhanced diagnostic capabilities and multidisciplinary care approaches. The complexity and diversity of URD necessitate collaborative efforts between various medical specialties. By leveraging innovative diagnostic tools, such as gene testing, we can enhance our understanding of these conditions and optimize patient management strategies.
Supporting information
S1 Checklist. Human participants research checklist.
https://figshare.com/s/39d3505fb878d39365b9.
https://doi.org/10.1371/journal.pone.0307454.s001
(DOCX)
References
- 1. Hughes DA, Tunnage B, Yeo ST: Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005, 98:829–36. pmid:16203824
- 2. Harari S: Why we should care about ultra-rare disease. Eur Respir Rev. 2016, 25:101–3. pmid:27246584
- 3. Sorenson C, Drummond M, Kanavos P, Mcguire A: NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE). 2008.
- 4. Perolla A, Çalliku E, Cili A, Caja T, Pulluqi P, Ivanaj A: Uncovering the Challenges of Rare Diseases: Insights From a Retrospective Cross-Sectional Study in Albania (2005–2022). Cureus. 2024, 16:. pmid:38222997
- 5. Hilt EE, Ferrieri P: Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases. Genes (Basel). 2022, 13:. pmid:36140733
- 6. Nellist M, Brouwer RWW, Kockx CEM, et al.: Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet. 2015, 16:10–10. pmid:25927202
- 7. Metzker ML: Sequencing technologies—the next generation. Nat Rev Genet. 2010, 11:31–46. pmid:19997069
- 8. Behjati S, Tarpey PS: What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013, 98:236–8. pmid:23986538
- 9. Kovesdi E, Ripszam R, Postyeni E, et al.: Whole Exome Sequencing in a Series of Patients with a Clinical Diagnosis of Tuberous Sclerosis Not Confirmed by Targeted TSC1/TSC2 Sequencing. Genes 2021, Vol 12, Page 1401. 2021, 12:1401. pmid:34573383
- 10. National Diabetes Statistics Report | Diabetes | CDC. Accessed: January 3, 2024. https://www.cdc.gov/diabetes/data/statistics-report/index.html.
- 11. Marwaha S, Knowles JW, Ashley EA: A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022, 14:. pmid:35220969
- 12. Fu MP, Merrill SM, Sharma M, Gibson WT, Turvey SE, Kobor MS: Rare diseases of epigenetic origin: Challenges and opportunities. Front Genet. 2023, 14:. pmid:36814905
- 13. RARE Disease Facts—Global Genes. Accessed: January 3, 2024. https://globalgenes.org/rare-disease-facts/.
- 14. Miao H, Zhou J, Yang Q, et al.: Long-read sequencing identified a causal structural variant in an exome-negative case and enabled preimplantation genetic diagnosis. Hereditas. 2018, 155:32. pmid:30279644
- 15. Al-Abdulkareem AA, Ballal SG: Consanguineous marriage in an urban area of Saudi Arabia: rates and adverse health effects on the offspring. J Community Health. 1998, 23:75–83. pmid:9526727
- 16. Hamamy H: Consanguineous marriages: Preconception consultation in primary health care settings. J Community Genet. 2012, 3:185. pmid:22109912
- 17. Yan X, He S, Dong D: Determining How Far an Adult Rare Disease Patient Needs to Travel for a Definitive Diagnosis: A Cross-Sectional Examination of the 2018 National Rare Disease Survey in China. Int J Environ Res Public Health. 2020, 17:. pmid:32182694
- 18. Marwaha S, Knowles JW, Ashley EA: A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med 2022 141. 2022, 14:1–22. pmid:35220969
- 19. Global Commission—Rare Diseases International. Accessed: January 3, 2024. https://www.rarediseasesinternational.org/global-commission/.
- 20. Smith CIE, Bergman P, Hagey DW: Estimating the number of diseases—the concept of rare, ultra-rare, and hyper-rare. iScience. 2022, 25:. pmid:35856030
- 21. Landrum MJ, Chitipiralla S, Brown GR, et al.: ClinVar: improvements to accessing data. Nucleic Acids Res. 2020, 48:D835–44. pmid:31777943
- 22. Vihinen M: Measuring and interpreting pervasive heterogeneity, poikilosis. FASEB bioAdvances. 2021, 3:611–25. pmid:34377957
- 23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008, 61:344–9. pmid:18313558
- 24. Council NC: Ultra Orphan Drugs. NICE Citizens Counc Reports. Published Online First: 19 November 2004.
- 25. Richards CS, Bale S, Bellissimo DB, et al.: ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008, 10:294–300. pmid:18414213
- 26. Tammimies K, Marshall CR, Walker S, et al.: Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. JAMA. 2015, 314:595–903. pmid:26325558
- 27. Jia J, Shi T: Towards efficiency in rare disease research: what is distinctive and important? Sci China Life Sci. 2017, 60:686–91. pmid:28639105
- 28. Carmichael N, Tsipis J, Windmueller G, Mandel L, Estrella E: ‘Is it going to hurt?’: the impact of the diagnostic odyssey on children and their families. J Genet Couns. 2015, 24:325–35. pmid:25277096
- 29. Garcia-Rosa S, Brenha B de F, Rocha VF da, Goulart E, Araujo BHS: Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies. Curr Neuropharmacol. 2021, 19:813. pmid:32933463
- 30. Anney RJL, Avbersek A, Balding D, et al.: Genetic determinants of common epilepsies: A meta-analysis of genome-wide association studies. Lancet Neurol. 2014, 13:893–903. pmid:25087078
- 31. Bryson A, Petrou S: SCN1A channelopathies: Navigating from genotype to neural circuit dysfunction. Front Neurol. 2023, 14:. pmid:37139072
- 32. Dichgans M, Freilinger T, Eckstein G, et al.: Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet (London, England). 2005, 366:371–7. pmid:16054936
- 33. Pizzino A, Whitehead M, Sabet Rasekh P, et al.: Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy. Am J Med Genet A. 2018, 176:1443. pmid:29696782
- 34. Muthaffar OY, Jan MMS, Alyazidi AS, Alotibi TK, Alsulami EA: Insight into Genetic Mutations of SZT2: Is It a Syndrome? Biomedicines. 2023, 11:. pmid:37760843
- 35. Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F: Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev. 2023, 103:433. pmid:35951482
- 36. Schossig A, Wolf NI, Fischer C, et al.: Mutations in ROGDI Cause Kohlschütter-Tönz Syndrome. Am J Hum Genet. 2012, 90:701. pmid:22424600
- 37. Sidore C, Orrù V, Cocco E, et al.: PRF1 mutation alters immune system activation, inflammation and risk of autoimmunity. Mult Scler. 2021, 27:1332. pmid:33566725
- 38. Voskoboinik I, Whisstock JC, Trapani JA: Perforin and granzymes: Function, dysfunction and human pathology. Nat Rev Immunol. 2015, 15:388–400. pmid:25998963
- 39. Chaudhry MS, Gilmour KC, House IG, et al.: Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition. Oncoimmunology. 2016, 5:. pmid:27622035
- 40. Muthaffar OY, Alqarni A, Shafei JA, Bahowarth SY, Alyazidi AS, Naseer MI: Childhood-related neural genotype-phenotype in ATP1A3 mutations: comprehensive analysis. Genes Genomics. 2024, 46:. pmid:38243045
- 41. Zou S, Lan YL, Gong Y, Chen Z, Xu C: The role of ATP1A3 gene in epilepsy: We need to know more. Front Cell Neurosci. 2023, 17:. pmid:36866063
- 42. Holm R, Toustrup-Jensen MS, Einholm AP, Schack VR, Andersen JP, Vilsen B: Neurological disease mutations of α3 Na+,K+-ATPase: Structural and functional perspectives and rescue of compromised function. Biochim Biophys Acta. 2016, 1857:1807–28. pmid:27577505
- 43. Yoo T, Cho H, Park H, Lee J, Kim E: Shank3 Exons 14–16 Deletion in Glutamatergic Neurons Leads to Social and Repetitive Behavioral Deficits Associated With Increased Cortical Layer 2/3 Neuronal Excitability. Front Cell Neurosci. 2019, 13:. pmid:31649512
- 44. Muthaffar O, Clinical AA-J of B and, 2022 U: Phelan-McDermid syndrome: a case report and review of the literature. J Biochem Clin Genet. 2022, 5(2):053–8.
- 45. Feng YCA, Howrigan DP, Abbott LE, et al.: Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. Am J Hum Genet. 2019, 105:267–82. pmid:31327507
- 46. Guerrini R, Marini C, Mantegazza M: Genetic Epilepsy Syndromes Without Structural Brain Abnormalities: Clinical Features and Experimental Models. Neurotherapeutics. 2014, 11:269. pmid:24664660
- 47. Tumienė B, Riera MDT, Grikiniene J, Samaitiene-Aleknienė R, Monavari AA, Sykut-Cegielska J, et al: Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives. J Multidiscip Healthc. 2022, 15:553. pmid:35387391
- 48. Shenfield GM: Genetic Polymorphisms, Drug Metabolism and Drug Concentrations. Clin Biochem Rev. 2004, 25:203. pmid:18458715
- 49. Talevi A, Bellera CL: Drug Absorption. ADME Process Pharm Sci Dosage, Des Pharmacother Success. 2023, 11–96.
- 50. Reynolds A, Vranic-Peters M, Lai A, Grayden DB, Cook MJ, Peterson A: Prognostic interictal electroencephalographic biomarkers and models to assess antiseizure medication efficacy for clinical practice: A scoping review. Epilepsia. 2023, 64:1125–74. pmid:36790369
- 51. Wolking S, Campbell C, Stapleton C, et al.: Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Front Pharmacol. 2021, 12:688386. pmid:34177598
- 52. Witt S, Schuett K, Wiegand-Grefe S, Boettcher J, Quitmann J: Living with a rare disease—experiences and needs in pediatric patients and their parents. Orphanet J Rare Dis. 2023, 18:1–16.
- 53. Elliott AM: Genetic Counseling and Genome Sequencing in Pediatric Rare Disease. Cold Spring Harb Perspect Med. 2020, 10:. pmid:31501267
- 54. Alqahtani AS, Alotibi RS, Aloraini T, et al.: Prospect of genetic disorders in Saudi Arabia. Front Genet. 2023, 14:. pmid:37799141
- 55. Monies D, Abouelhoda M, AlSayed M, et al.: The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes. Hum Genet. 2017, 136:921–39. pmid:28600779